People taking new weight-loss drugs say they curb cravings for booze, drugs, and nicotine. Did scientists inadvertently ...

Surprising research strongly suggests semaglutide can help fight substance use disorder. Why aren't we using it?

Over 137 million US adults are eligible for semaglutide, mainly for weight loss, diabetes, or cardiovascular prevention. Semaglutide is the top-selling drug in 2023, but affordability remains a ...

Does Compounded Semaglutide Work for Weight Loss? Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But it’s important to ...

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have been associated with at least 100 hospitalizations and 10 deaths ...

Most people regain some of the weight they lost after stopping semaglutide. However, physical activity and a balanced diet may help you keep some weight off. Share on Pinterest LeoPatrizi/Getty ...

CVS Caremark has removed several therapies to treat patients with diabetes in favor of newer products and generics, and is ...

Unsurprisingly, the patients taking the active semaglutide lost way more weight than their placebo counterparts — but they also experienced dramatic reductions in their pain scales, with an ...

The mean change in body weight from baseline to week 68 was −13.7% with semaglutide and −3.2% with placebo (P<0.001). The mean change in the WOMAC pain score at week 68 was −41.7 points with ...

Semaglutide, commonly known by its brand names Wegovy® and Ozempic®, has become a hot topic in the health and wellness world, especially for its weight loss benefits. Originally developed for ...

In the phase 3 Essence trial, a once-weekly dose of semaglutide 2.4 mg helped to improve liver fibrosis with no worsening of steatohepatitis and to resolve steatohepatitis with no worsening of ...

At week 68, the mean change in the Western Ontario and McMaster Universities Osteoarthritis Index pain score was −41.7 and −27.5 points with semaglutide and placebo, respectively.